Biostar Pharmaceuticals, Inc.
BSPM · OTC
9/30/2017 | 6/30/2017 | 3/31/2017 | 12/31/2016 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | – | – | – | -11.6% |
| R&D Expenses | $0 | $0 | $0 | $1 |
| G&A Expenses | $1 | $2 | $1 | $1 |
| SG&A Expenses | $1 | $2 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | -$8 |
| Operating Expenses | $1 | $2 | $1 | -$6 |
| Operating Income | -$1 | -$2 | -$1 | $6 |
| % Margin | – | – | – | 1,865% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$0 | -$1 | -$1 | $6 |
| Tax Expense | $0 | $0 | $0 | $3 |
| Net Income | -$0 | -$1 | -$1 | $3 |
| % Margin | – | – | – | 1,066.1% |
| EPS | -0.05 | -0.5 | -0.38 | 1.61 |
| % Growth | 90% | -31.6% | -123.6% | – |
| EPS Diluted | -0.05 | -0.5 | -0.38 | 1.61 |
| Weighted Avg Shares Out | 3 | 3 | 3 | 3 |
| Weighted Avg Shares Out Dil | 3 | 3 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | -$1 | -$1 | $6 |
| % Margin | – | – | – | 1,992.8% |